Updates are available Correction dated 2026-01-14
Click to view Correction: https://doi.org/10.1007/s10120-025-01709-4
-
Authors
Yasufuku, Itaru
Kinoshita, Takahiro
Bando, Etsuro
Kurokawa, Yukinori
Fujisaki, Muneharu
Ojima, Hitoshi
Arigami, Takaaki
Fujibayashi, Seito
Watanabe, Masahiro
Furukawa, Kenichiro
Matsuhashi, Nobuhisa
Terashima, Masanori https://orcid.org/0000-0002-2967-8267
- License Information
-
More Information
Article History
Received: 11 August 2025
Accepted: 23 October 2025
First Online: 18 November 2025
Change Date: 23 December 2025
Change Type: Update
Change Details: The original online version of this article was revised to amend the errors in table 1 and 5.
Change Date: 14 January 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10120-025-01709-4
Declarations
:
: EB had received personal fees from Johnson & Johnson Innovative Medicine, Medtronic Japan, Tsumura Corporation, Daiichi Sankyo, Intuitive, and ONO PHARMACEUTICAL CO., LTD. YK had received research grants from Taiho Pharmaceutical and Yakult Honsha, and personal fees from Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squibb, Astellas Pharma, Daiichi Sankyo, MSD, Johnson & Johnson, Medtronic Japan, MC Medical, andStryker. TA had received personal fees from Bristol Myers Squib, and Daiichi Sankyo. NM had received research grants from Asahi Kasei Pharma, Chugai Pharm, Covidien Japan, Daiichi Sankyo, Eisai, e-NA Biotec, EP-CRSU, EPS Corporation, JMS, Johnson & Johnson, Kaken Pharm., Kyowa Kirin, MSD, Nippon Kayaku, Ono Pharm., ShiftZero K.K., Taiho Pharm., TERUMO, and Toray Medical, and received personal fees from Abbott, Alfresa Pharma, AMCO Inc., Asahi Kasei Pharma, Astellas Pharma Inc., AstraZeneca, Bayer Yakuhin, Bristol-Myers Squibb, Chugai Pharm., Covidien Japan, Daiichi Sankyo, EA Pharma, Eisai, Eli Lilly Japan, Guardant Health Japan Corp, Gunze Medical Limited, Intuitive Surgical, Johnson & Johnson, Kaken Pharm., Kyowa Kirin, MC Medical, Merck Biopharma Japan, Miyarisan Pharm., MSD, Novartis, Olympus Marketing, Inc., Ono Pharm., Stryker, Taiho Pharm., TAKATA Pharm, Takeda Pharm., TERUMO, Tsumura, Viatris, Yakult Honsha, and ZERIA Pharm. MT received personal fees from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol Myers Squib Japan K.K., Yakult Honsha Co., Ltd., Astra Zeneca Co. Ltd., Eli Lilly Japan K.K., Astellas Pharm. Inc., Daiichi Sankyo Ltd., Johnson and Johnson K.K., Medtronic Japan Co., Ltd., Intuitive Japan Inc., and Olympus Co., Ltd. IY, TK, MF, TO, SF, MW, and KF had had no conflict of interest.
